Veeva Systems Inc. $VEEV Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC increased its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 193.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 41,395 shares of the technology company’s stock after purchasing an additional 27,312 shares during the period. Intech Investment Management LLC’s holdings in Veeva Systems were worth $11,921,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Mutual of America Capital Management LLC increased its stake in Veeva Systems by 13.8% during the 1st quarter. Mutual of America Capital Management LLC now owns 3,577 shares of the technology company’s stock worth $829,000 after buying an additional 433 shares during the period. CWM LLC raised its position in shares of Veeva Systems by 8.3% during the 1st quarter. CWM LLC now owns 8,785 shares of the technology company’s stock worth $2,035,000 after acquiring an additional 676 shares in the last quarter. Signaturefd LLC raised its holdings in Veeva Systems by 22.1% during the first quarter. Signaturefd LLC now owns 1,507 shares of the technology company’s stock worth $349,000 after purchasing an additional 273 shares in the last quarter. Wealthfront Advisers LLC lifted its position in Veeva Systems by 58.7% in the first quarter. Wealthfront Advisers LLC now owns 6,706 shares of the technology company’s stock valued at $1,553,000 after acquiring an additional 2,481 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Veeva Systems by 3.9% in the 1st quarter. Victory Capital Management Inc. now owns 71,497 shares of the technology company’s stock valued at $16,561,000 after purchasing an additional 2,677 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on VEEV shares. Oppenheimer reiterated an “outperform” rating and set a $325.00 price target on shares of Veeva Systems in a research note on Thursday, August 28th. Weiss Ratings reissued a “hold (c+)” rating on shares of Veeva Systems in a report on Wednesday, October 8th. Evercore ISI increased their price target on shares of Veeva Systems from $285.00 to $295.00 and gave the company an “in-line” rating in a research report on Thursday, August 28th. BMO Capital Markets began coverage on shares of Veeva Systems in a research report on Thursday. They issued a “market perform” rating and a $300.00 price objective for the company. Finally, TD Cowen raised shares of Veeva Systems from a “hold” rating to a “buy” rating and raised their target price for the stock from $297.00 to $380.00 in a research report on Tuesday, October 7th. Seventeen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Veeva Systems currently has an average rating of “Moderate Buy” and an average target price of $307.28.

Veeva Systems Price Performance

Shares of Veeva Systems stock opened at $293.24 on Friday. Veeva Systems Inc. has a 1-year low of $201.54 and a 1-year high of $310.50. The business has a 50-day moving average of $288.89 and a 200-day moving average of $277.67. The company has a market capitalization of $48.06 billion, a PE ratio of 60.21, a P/E/G ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.90 by ($0.64). The business had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, equities analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Activity

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total value of $1,839,720.00. Following the completion of the transaction, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Jonathan Faddis sold 720 shares of the stock in a transaction on Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the sale, the senior vice president directly owned 7,868 shares in the company, valued at $2,345,608.16. This trade represents a 8.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is currently owned by insiders.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.